AAO: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

Video
Conference|AAO

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.


Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Recent Videos
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A person holds an Ozempic injector pen. Image credit: ©alones – stock.adobe.com

European Medicines Agency will assess semaglutide for link to NAION

Hattie Hayes
December 20th 2024
Article

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A person in a business suit holds a lit-up lightbulb. Image credit: ©kamiphotos – stock.adobe.com

EssilorLuxottica announces agreement for acquisition of Espansione Group

Sydney M Crago
December 17th 2024
Article

Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A gloved hand holds two syringes full of fluid. Image credit: ©StudioLaMagica – stock.adobe.com

European Medicines Agency approves faricimab (Vabysmo) 6.0 mg single-dose prefilled syringe

Hattie Hayes
December 13th 2024
Article

The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular oedema and macular oedema following retinal vein occlusion

A person's hand touches a digital output of a chart with several different data sets represented. Image credit: ©WrightStudio – stock.adobe.com

Investigators report findings on serum inflammatory biomarkers in patients with macular oedema

Lynda Charters
December 12th 2024
Article

A retrospective study assessed elevated neutrophil-to-lymphocyte ratios and systemic immune-inflammation index levels in patients with different subtypes of DMO

© 2024 MJH Life Sciences

All rights reserved.